Exclusive content at CPhI North America

Learning never stops in the world of pharma. To make sure you’re up to date on all the latest developments in the industry, we will be bringing you 4 weeks of free virtual conference content at CPhI North America. Starting July 19, each week has its own track or theme to make sure you know when to tune in so you don't miss out.

Wellbeing at Work

The pandemic has brought fresh challenges for our mental health and wellbeing. With many of us living through lockdowns, working in our makeshift home offices and juggling home-schooling or caring for relatives, it's important to find time to look after you. Our Wellbeing Series encourages you to shift perspective inwards and take some time for you.

This Year's Content Tracks

US Market Insights

During week 1 (July 19-23) we will focus on US Market Insights with topics such as:

  • US Pharmaceutical Market Outlook 2021 (In Partnership with Global Business Reports)
  • Regulatory Update 2021 (Dr Scott Gottlieb, Physician & former FDA Commissioner)
  • How will the New Administration Impact the US Pharma Market?
  • M&A Climate and Current Market Dynamics

Product Innovation

Week 2 (July 26-30) of our digital content program is dedicated to celebrating innovation across biologics, manufacturing technologies, outsourcing, drug development and formulation, packaging and drug delivery solutions:

  • Custom Webinars
  • Learning Labs

Future Forecasting, Diversity, Equality & Inclusion

During week 3 (August 2-6) we will focus on Future Forecasting and Diversity, Equality and Inclusion

  • How Diversity of Leadership can Incite Change for Patients from all Backgrounds
  • What role will Pharma play in the Healthcare system of 2022?
  • The Women in Leadership Forum: Navigating the Road to Investment for Female Founders
  • De-risking Drug Development with Digital
  • The Lasting Impact of COVID-19 on Drug Development
  • Celebrating Innovation in the race to develop COVID-19 Vaccines
  • Building Supply Chain Resiliency & Continuity of Supply
  • The Real Cost of Bringing Manufacturing Home
  • Trends in Cell & Gene Therapies
  • The Biosimilar Competition Landscape- Looking to the Future 
  • Exploring how Biopharma Innovation will Change Our Industry

Podcast Series

In the final week (August 9-13) we will host a three-part series on the Quality & Safety of Drug Development

Prepare Now with the Help of Experts

Our 2021 Pharma Outlook report has been published in collaboration with some of Pharma’s biggest names to provide key insights that will help you navigate the next 12 months and grow your business.

Get the Latest News

US Pharma Outlook

US Pharma Outlook

The new decade has rolled in, bringing new and unprecedented challenges. New products with shorter lifecycles, aging population and rigorous regulatory scrutiny will play a role in shaping the industry. In this article, leading industry experts in the region share their views on what the most important trends will be for this year, and this decade

The Future of Drug Development and Delivery

The Future of Drug Development and Delivery

How is biopharma striking a balance between modernizing drug development & delivery and the effort to rein in R&D expenses? While change is unlikely to be quick, there is consensus that pharma does need to embrace changes in drug development and delivery fully explore the wide range of opportunities that exist. 

Bioprocess and Continuous Manufacturing

Bioprocess and Continuous Manufacturing

Biopharma comprises 25% of the total pharma market and revenues have gone up by over 6000% from the 1990s to now. What are companies doing to keep up with this growth and innovation? Read this article to find out. 

In Other News

Artificial Intelligence: Moving beyond efficiency gains in drug development

Artificial Intelligence: Moving beyond efficiency gains in drug development

Is the pharma industry making the most of AI’s potential when it comes to accelerating and enhancing pharmaceutical drug development? The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making.

Looking beyond the one-shop-stop hype: what really drives CDMOs

Looking beyond the one-shop-stop hype: what really drives CDMOs

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating.

Unlocking the potential of cannabinoid-derived drugs

Unlocking the potential of cannabinoid-derived drugs

FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome.

How Empathy Can Inspire Great Leadership

How Empathy Can Inspire Great Leadership

What role does empathy play in building successful teams, and in turn, businesses? Read on to find out how empathetic leadership promotes a strong corporate culture, and lays a strong foundation for success.